scholarly journals Computer-aided heterogeneity analysis in breast MR imaging assessment of ductal carcinoma in situ: Correlating histologic grade and receptor status

2017 ◽  
Vol 46 (6) ◽  
pp. 1748-1759 ◽  
Author(s):  
Shinn-Huey S. Chou ◽  
Eva C. Gombos ◽  
Sona A. Chikarmane ◽  
Catherine S. Giess ◽  
Jagadeesan Jayender
Keyword(s):  
Mr Imaging ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Histologic Grade ◽  
Receptor Status ◽  
Breast Mr ◽  
Computer Aided ◽  
Heterogeneity Analysis

scholarly journals Ductal Carcinoma in Situ: Quantitative Preoperative Breast MR Imaging Features Associated with Recurrence after Treatment

Radiology ◽  
2017 ◽  
Vol 285 (3) ◽  
pp. 788-797 ◽  
Author(s):  
Jing Luo ◽  
Brian S. Johnston ◽  
Averi E. Kitsch ◽  
Daniel S. Hippe ◽  
Larissa A. Korde ◽  
...  
Keyword(s):  
Mr Imaging ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Imaging Features ◽  
Breast Mr

Three-dimensional RODEO breast MR imaging of lesions containing ductal carcinoma in situ.

Radiology ◽  
1996 ◽  
Vol 201 (2) ◽  
pp. 427-432 ◽  
Author(s):  
C E Soderstrom ◽  
S E Harms ◽  
D S Copit ◽  
W P Evans ◽  
D A Savino ◽  
...  
Keyword(s):  
Mr Imaging ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Three Dimensional ◽  
Breast Mr

The role of breast MR imaging in pre-operative determination of invasive disease for ductal carcinoma in situ diagnosed by needle biopsy

2011 ◽  
Vol 22 (6) ◽  
pp. 1255-1264 ◽  
Author(s):  
Mariko Goto ◽  
Sachiko Yuen ◽  
Kentaro Akazawa ◽  
Kaori Nishida ◽  
Eiichi Konishi ◽  
...  
Keyword(s):  
Mr Imaging ◽  
Ductal Carcinoma In Situ ◽  
Needle Biopsy ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Invasive Disease ◽  
Breast Mr

Breast MR-Imaging of Ductal Carcinoma In Situ: A Systematic Review

2009 ◽  
Vol 13 (3-4) ◽  
pp. 112-121 ◽  
Author(s):  
A. C. Schmitz ◽  
M. L. J. Smits ◽  
W. Veldhuis ◽  
E. van der Wall ◽  
R. van Hillegersberg ◽  
...  
Keyword(s):  
Systematic Review ◽  
Mr Imaging ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Breast Mr

Ductal Carcinoma in Situ of the Breast: MR Imaging Findings with Histopathologic Correlation

Radiographics ◽  
2010 ◽  
Vol 30 (6) ◽  
pp. 1673-1687 ◽  
Author(s):  
Mahmud Mossa-Basha ◽  
Gina M. Fundaro ◽  
Biren A. Shah ◽  
Sharif Ali ◽  
Milan V. Pantelic
Keyword(s):  
Mr Imaging ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Imaging Findings ◽  
Breast Mr

scholarly journals Study of Estrogen Receptor and Progesterone Receptor Expression in Breast Ductal Carcinoma In Situ by Immunohistochemical Staining in ER/PgR-Negative Invasive Breast Cancer

ISRN Oncology ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Andrei Dobrescu ◽  
Monique Chang ◽  
Vatsala Kirtani ◽  
George K. Turi ◽  
Randa Hennawy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma In Situ ◽  
Invasive Breast Cancer ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Receptor Expression ◽  
Invasive Cancer ◽  
Positive Staining ◽  
Receptor Status

Background. To our knowledge, the hormone receptor status of noncontiguous ductal carcinoma in situ (DCIS) occurring concurrently in ER/PgR-negative invasive cancer has not been studied. The current study was undertaken to investigate the ER/PgR receptor status of DCIS of the breast in patients with ER/PgR-negative invasive breast cancer. Methods. We reviewed the immunohistochemical (IHC) staining for ER and PgR of 187 consecutive cases of ER/PgR-negative invasive breast cancers, collected from 1995 to 2002. To meet the criteria for the study, we evaluated ER/PgR expression of DCIS cancer outside of the invasive breast cancer. Results. A total of 37 cases of DCIS meeting the above criteria were identified. Of these, 16 cases (43.2%) showed positive staining for ER, PgR, or both. Conclusions. In our study of ER/PgR-negative invasive breast cancer we found that in 8% of cases noncontiguous ER/PR-positive DCIS was present. In light of this finding, it may be important for pathologists to evaluate the ER/PgR status of DCIS occurring in the presence of ER/PgR-negative invasive cancer, as this subgroup could be considered for chemoprevention.

MR imaging of ductal carcinoma in situ.

Radiology ◽  
1997 ◽  
Vol 202 (2) ◽  
pp. 413-420 ◽  
Author(s):  
S G Orel ◽  
M H Mendonca ◽  
C Reynolds ◽  
M D Schnall ◽  
L J Solin ◽  
...  
Keyword(s):  
Mr Imaging ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma

scholarly journals Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24

2012 ◽  
Vol 30 (12) ◽  
pp. 1268-1273 ◽  
Author(s):  
D. Craig Allred ◽  
Stewart J. Anderson ◽  
Soonmyung Paik ◽  
D. Lawrence Wickerham ◽  
Iris D. Nagtegaal ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Significant Benefit ◽  
Adjuvant Tamoxifen ◽  
Receptor Status ◽  
Er Positive

Purpose The NSABP (National Surgical Adjuvant Breast and Bowel Project) B-24 study demonstrated significant benefit with adjuvant tamoxifen in patients with ductal carcinoma in situ (DCIS) after lumpectomy and radiation. Patients were enrolled without knowledge of hormone receptor status. The current study retrospectively evaluated the relationship between receptors and response to tamoxifen. Patients and Methods Estrogen (ER) and progesterone receptors (PgR) were evaluated in 732 patients with DCIS (41% of original study population). An experienced central laboratory determined receptor status in all patient cases with available paraffin blocks (n = 449) by immunohistochemistry (IHC) using comprehensively validated assays. Results for additional patients (n = 283) determined by various methods (primarily IHC) were available from enrolling institutions. Combined results were evaluated for benefit of tamoxifen by receptor status at 10 years and overall follow-up (median, 14.5 years). Results ER was positive in 76% of patients. Patients with ER-positive DCIS treated with tamoxifen (v placebo) showed significant decreases in subsequent breast cancer at 10 years (hazard ratio [HR], 0.49; P < .001) and overall follow-up (HR, 0.60; P = .003), which remained significant in multivariable analysis (overall HR, 0.64; P = .003). Results were similar, but less significant, when subsequent ipsilateral and contralateral, invasive and noninvasive, breast cancers were considered separately. No significant benefit was observed in ER-negative DCIS. PgR and either receptor were positive in 66% and 79% of patients, respectively, and in general, neither was more predictive than ER alone. Conclusion Patients in NSABP B-24 with ER-positive DCIS receiving adjuvant tamoxifen after standard therapy showed significant reductions in subsequent breast cancer. The use of adjuvant tamoxifen should be considered for patients with DCIS.

Ductal Carcinoma in Situ: Computer-aided Detection in Screening Mammography

Radiology ◽  
2006 ◽  
Vol 241 (3) ◽  
pp. 689-694 ◽  
Author(s):  
Vidya R. Pai ◽  
Nancy E. Gregory ◽  
Ann E. Swinford ◽  
Murray Rebner
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Screening Mammography ◽  
Computer Aided Detection ◽  
Computer Aided
Sign in / Sign up

Export Citation Format

Share Document